MKMikhail Karpenko

Mikhail Karpenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mikhail Karpenko has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Donor heart coronary artery bypass grafting

    by M. L. Gordeev, G. V. Nikolaev, S. S. Stepanov, V. K. Grebennik, A. M. Osadchiy, D. V. Bendov, P. A. Fedotov, A. B. Ivanova, N. E. Morozov, M. A. Simonenko, et al.

    Objective: to evaluate the initial experience of performing simultaneous heart transplant (HT) with coronary artery bypass grafting (CABG) at Almazov National Medical Research Centre in St. Petersburg. Materials and methods. Outcomes of 196 HT performed between January 1, 2016, and January 1, 2025, were analyzed. Patients were divided into two groups: 16 recipients who underwent combined HT + CABG (Group 1) and 180 recipients who underwent standard HT (Group 2). The groups were compared using the following parameters: duration of surgery, graft ischemic time, duration of cardiopulmonary bypass (CPB), duration of inotropic therapy, length of stay in the intensive care unit (ICU), 30-day mortality, and one-year survival. Results. The operative time was longer in Group 1, at 312 (286–415); 2020; 1130 min, compared with Group 2, at 268 (225–320); 150; 2150 min (p = 0.007). Group 1 also demonstrated a significant increase in graft ischemic time and CPB duration compared to group 2. Median graft ischemic time in Group 1 was 156 (146–180); 120, 240 min, versus 140 (120–160); 40, 240 min in Group 2 (p = 0.021). CPB duration was 159 (133–180); 101, 214 min in Group 1 and 128 (101–162); 71–350 min in Group 2 (p = 0.015). Despite the more complex nature of the intervention in Group 1, no statistically significant differences were observed between the groups in the duration of inotropic therapy or length of stay in the ICU. Although the 30-day mortality rate was higher in Group 1 than in Group 2 (18.7% vs . 7.8%), this difference did not reach statistical significance (p = 0.136). One-year survival rates were comparable between the two groups. Conclusion. Simultaneous HT and CABG procedures are associated with longer operative time, prolonged graft ischemia, and longer CPB duration compared with standard HT. However, no differences were observed in the duration of inotropic therapy or early postoperative period. Combined HT and CABG procedures are technically feasible, with 30-day mortality and one-year survival rates comparable to those of standard HT. The use of donor hearts with underlying coronary artery pathology may expand donor selection criteria and increase the number of HT procedures performed.

  • Open Access

    Vaccination against a COVID-19 and predictors of COVID-19 development in patients after heart transplantation: a Russian multicenter observational study

    by M. A. Simonenko, P. A. Fedotov, A. N. Kostomarov, E. D. Kosmachova, M. V. Kolodina, И. В. Утьманова, T. S. Golovina, I. Yu. Melnikov, I. G. Zubareva, N. A. Gorbunova, et al.

    Patients after heart transplantation (HT) have a high risk of infectious complications, including hospitalization and death due to SARS-CoV-2 infection. However, both patients with heart failure and heart recipients often face vaccination refusal due to insufficient data on its safety in this population.Aim. To evaluate the efficacy and safety of vaccination against a coronavirus disease 2019 (COVID-19) in individuals after HT.Material and methods. This retrospective analysis of a multicenter registry created on the basis of the "Database of patients after heart transplantation depending on the vaccination against a COVID-19" (№ 2022622422, Simonenko M. A., Fedotov P. A.) was performed. It included 47 indicators and blinded results of observation of 367 heart recipients who received post-transplant support from February 2020 to May 2023 and lived in 7 regions of Russia.Results. Most patients included in the study were men (80%, n=294). The mean age of patients at the time of vaccination was 53±13 years. Immunosuppression was induced in 82,3% of patients and they then received maintenance immunosuppressive therapy with calcineurin inhibitors, mycophenolic acid/ mycophenolate mofetil, or everolimus, and half of them, by the time after HT, received glucocorticosteroids. It is important to note that 67% (n=245) of the recipients included in the analysis did not have COVID-19 before HT, and another 33% (n=122) had COVID-19 after HT without being vaccinated. As of May 2023, almost half of the registry participants (47%; n=174) were vaccinated against COVID-19 using the Gam-Covid-Vac (Sputnik V) vaccine in 94% (n=164) of individuals and Sputnik Light in 6% (n=10). Before HT, immunization was carried out in only 6,5% of the studied subjects. Mild side effects such as subfebrile fever (10%), fever (4%), general weakness (11%), or headache (2%) developed in 17% (n=30) of patients within 24-48 hours after vaccination. In addition, 18% (n=32) of patients in the vaccinated group were subsequently infected with COVID-19, of which only 5 people had a moderate course. After 1,5-2 months, two patients developed post-COVID complications such as exacerbation of bronchial asthma (n=1) and post-COVID alveolitis (n=1), which were stopped by glucocorticosteroid therapy. In the absence of vaccination, the relative risk of COVID-19 compared to vaccinated patients was 2,66 (95% confidence interval: 1,88; 3,75). Vaccination against COVID-19 is associated with a 30,9% reduction in the absolute risk of COVID-19, and to prevent 1 case of COVID-19, 4 heart recipients need to be vaccinated (NNT=3,2).Conclusion. Vaccination against COVID-19 in heart recipients is safe and associated with a lower incidence of COVID-19 and a milder course of COVID-19 compared to unvaccinated patients. Predictors of COVID-19 infection in the studied sample were male sex, the use of mycophenolic acid/mycophenolate mofetil, and the induction of immunosuppression.


  • Changes of mental and physical components of quality of life in patients after heart transplantation: experience of the Almazov National Medical Research Center

    by M. A. Simonenko, P. A. Fedotov, M. Yu. Sitnikova, V. A. Bart, L. A. Vasilieva, A. V. Berezina, M. A. Karpenko

    Aim. To assess the changes of quality of life (QoL) in patients after heart transplantation (HTx) and identifying factors associated with its changes. Material and methods. We retrospectively assessed the register created on the basis of the original database "Mental status of patients after heart transplantation: experience of the Almazov National Medical Research Center" № 2023622138. There were following inclusion criteria: recipients aged over 18 years with preserved cardiac transplant function (Simpson's left ventricular ejection fraction >55%) with a follow-up period >3 months after transplantation. After inclusion on the heart transplant waiting list, patients filled out the SF-36 questionnaire and a coping test, while then 3-6 months, 1 and 3 years after HTx — SF-36, a coping test and the International Physical Activity Questionnaire (IPAQ). Results. The mean age of recipients included in the study (n=112; 84 men) was 48±11-year-old. According to the SF-36 results after HTx, patients improved most of the indicators of physical QoL, except for Bodily Pain (BP), while the level of mental QoL increased by 3-6 months after surgery and did not undergo significant changes thereafter. According to the Lazarus coping test, during the 1 st year after HTx the level of coping mechanisms did not change, but by 3 years after the surgery there was a positive trend in the form of a gradual decrease. In the first 3-6 months after HTx, one third of the patients were physically active, the rest led a sedentary lifestyle. After HTx, the number of physically active recipients increased, and after 3 years they accounted for only half of the observed patients. According to the SF-36 and the coping test, the following components of QoL (BP, role-functioning physical, role-functioning emotional, vitality) and self-control were higher in physically active recipients. Other indicators did not change depending on physical activity (PA; p>0,05). There were no differences in SF-36, Lazarus test and IPAQ scores depending on whether patients worked after HTx or not. After HTx, there were no significant correlations between QoL indicators and recipients' sex, length of stay in the HTx waiting list and in the ICU after HTx, or the use of mechanical circulatory support prior to HTx. Conclusion. After HTx, physical QoL improved, remaining at a stable level during 3 years follow-up, and its positive changes were directly related to the PA of patients. Older age and lack of PA negatively affected post-transplant QoL. Compared with the results during stay in the HTx waiting list, 3-6 months after HTx, mental QoL improved and remained stable at 3 years after surgery, which was associated with the clinical condition of the patients and the normal functioning of the heart transplant. At the same time, the main factors that positively affected its dynamics were male sex, a sedentary lifestyle, as well as a lower level of the coping mechanism of escape-avoidance of the problem and a higher level of self-control.


  • Open Access

    Changes of mental and physical components of quality of life in patients after heart transplantation: experience of the Almazov National Medical Research Center

    by M. A. Simonenko, P. A. Fedotov, M. Yu. Sitnikova, V. A. Bart, L. A. Vasilieva, A. V. Berezina, M. A. Karpenko

    Aim. To assess the changes of quality of life (QoL) in patients after heart transplantation (HTx) and identifying factors associated with its changes.Material and methods. We retrospectively assessed the register created on the basis of the original database "Mental status of patients after heart transplantation: experience of the Almazov National Medical Research Center" № 2023622138. There were following inclusion criteria: recipients aged over 18 years with preserved cardiac transplant function (Simpson's left ventricular ejection fraction >55%) with a follow-up period >3 months after transplantation. After inclusion on the heart transplant waiting list, patients filled out the SF-36 questionnaire and a coping test, while then 3-6 months, 1 and 3 years after HTx — SF-36, a coping test and the International Physical Activity Questionnaire (IPAQ).Results. The mean age of recipients included in the study (n=112; 84 men) was 48±11-year-old. According to the SF-36 results after HTx, patients improved most of the indicators of physical QoL, except for Bodily Pain (BP), while the level of mental QoL increased by 3-6 months after surgery and did not undergo significant changes thereafter. According to the Lazarus coping test, during the 1st year after HTx the level of coping mechanisms did not change, but by 3 years after the surgery there was a positive trend in the form of a gradual decrease. In the first 3-6 months after HTx, one third of the patients were physically active, the rest led a sedentary lifestyle. After HTx, the number of physically active recipients increased, and after 3 years they accounted for only half of the observed patients. According to the SF-36 and the coping test, the following components of QoL (BP, role-functioning physical, role-functioning emotional, vitality) and self-control were higher in physically active recipients. Other indicators did not change depending on physical activity (PA; p>0,05). There were no differences in SF-36, Lazarus test and IPAQ scores depending on whether patients worked after HTx or not. After HTx, there were no significant correlations between QoL indicators and recipients' sex, length of stay in the HTx waiting list and in the ICU after HTx, or the use of mechanical circulatory support prior to HTx.Conclusion. After HTx, physical QoL improved, remaining at a stable level during 3 years follow-up, and its positive changes were directly related to the PA of patients. Older age and lack of PA negatively affected post-transplant QoL. Compared with the results during stay in the HTx waiting list, 3-6 months after HTx, mental QoL improved and remained stable at 3 years after surgery, which was associated with the clinical condition of the patients and the normal functioning of the heart transplant. At the same time, the main factors that positively affected its dynamics were male sex, a sedentary lifestyle, as well as a lower level of the coping mechanism of escape-avoidance of the problem and a higher level of self-control.


  • Open Access

    The intensity of thrombinogenesis and the activity of the protein C system in patients with coronary artery disease before and after endovascular revascularization postinfarction aneurysm of the left ventricle

    by G.A. Berezovskaya, N.N. Petrishchev, T.V. Lazovskaya, A.N. Yakovlev, M.A. Karpenko, Yu.SH. Khalimov

    Интенсивность тромбиногенеза и активность системы протеина С у больных с ишемической болезнью сердца до и после эндоваскулярной реваскуляризации

  • Open Access

    337.8: The Dynamic of Physical Capacity and Quality of Life in Recipients After Heart Transplantation

    by Maria Simonenko, Aelita Berezina, Petr Fedotov, Olga Tarasova, Tatiana Lelyavina, Mikhail Karpenko, Maria Sitnikova

  • Open Access

    Mortality risk factors in patients who are in heart transplantation waiting list

    by P. A. Fedotov, M. A. Simonenko, J. V. Sazonova, M. A. Bortsova, A. N. Kostomarov, M. A. Fedorova, A. E. Bautin, G. V. Nikolaev, M. L. Gordeev, M. A. Karpenko, et al.

    Objective: to estimate the survival of patients in the heart transplantation waiting list (HTx WL) at Almazov National Medical Research Centre (V.A. Almazov NMRC), Saint-Petersburg, Russia, from 2010 to 2018 and to define factors for death among these patients.Materials and methods: it was a single-centre retrospective study involving 151 patients with end-stage chronic heart failure (CHF) classes III-IV (NYHA) in the HTx WL.Results: the dynamic of decreasing mortality was revealed. Based on the results of constructing the discriminant function, four factors predicting the survival of patients in the HTx WL, namely, ACE inhibitors/ARBs, beta-blockers, status 1 of UNOS, CHF NYHA class IV, were pointed out. The model has sufficient resolving power but is not capable of predicting the outcome in the presence of acute decompensation of CHF.Conclusion: mortality in the HTx WL for the period 2010-2018 decreased that was associated with an active implementation of cardiac surgical methods as a «bridge» to transplant and optimal medical therapy, including ACE inhibitors/ARBs and beta-blockers in patients supported with inotropes (UNOS 1B). The greatest risk of mortality was found in CHF class IV and status 1 by UNOS.


  • New possibilities for predicting the resumption of clinical manifestations of coronary artery disease after endovascular intervention

    by G.A. Berezovskaya, T.V. Lazovskaya, D.A. Tarkhov, E.G. Malev, N.N. Petrishchev, M.A. Karpenko

    Новые возможности прогнозирования возобновления клинических проявлений ишемической болезни сердца после эндоваскулярной реваскуляризации

  • Defeat of the cardiovascular system in the new coronavirus infection COVID 19

    by Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Health of the Russian Federation, G.A. Berezovskaya, N.N. Petrishchev, E.V. Volkova, M.A. Karpenko, Yu.SH. Khalimov

    Поражение сердечно-сосудистой системы при новой коронавирусной инфекции COVID 19


  • COVID-19 management in heart transplanted recipients: registry of Almazov National Medical Research Centre

    by M. A. Simonenko, P. A. Fedotov, Yu. V. Sazonova, K. I. Monosova, M. Yu. Sitnikova, G. V. Nikolaev, M. L. Gordeev, M. A. Karpenko

    Aim      This study presents the experience of managing patients with COVID-19 after cardiac transplantation (CT). Material and methods  Infectious complications (IC) following CT are a leading cause for morbidity and mortality. A prolonged incubation period, atypical IC symptoms, and originally altered results of laboratory and instrumental diagnosis are characteristic of recipients due to immunosuppression. In 2020, the coronavirus infection (COVID-19) rapidly spread worldwide, and timely diagnosis and searching for effective treatments for this disease became a major challenge. From January 2010 through July 2020, 148 patients received orthotopic heart transplants at the V.A. Almazov National Medical Research Center; 34 of these patients died by the present time and were excluded from this analysis. 114 patients were included into the retrospective evaluation of results. These patients had been a part of the group followed up at the Center for more than a month. Results From March through July 2020, 12 (10.5 %) of 114 CT recipients were infected with the virus SARS-CoV-2. In 75 % (n=9) of the sick patients, the COVID-19 infection developed after more than one year after CT. From the first day of clinical symptoms, mycophenolic acid/everolimus were temporarily suspended. The outpatient treatment was started on the first day and included an antiviral therapy (oseltamivir), mucolytics (bromhexine), vitamin C, and anticoagulants. If the disease onset was associated with pyretic fever the empiric antibacterial levofloxacin treatment was administered due to a high risk of mixed infection. Hospitalized patients with moderately severe COVID-19 (n=3) were treated with oxygen inhalation through nasal cannula and prone position with a positive effect. Conclusion      Remote counseling of patients after CT and consistency of the outpatient treatment with recommendations of managing transplant physicians provided timely diagnosis of IC, early administration of treatment, and the absence of COVID-19 complications. Reducing the regimen of immunosuppressive therapy (antiproliferative agents) for up to 14 days facilitated infection control and was not associated with acute rejection crisis and/or impairment of the transplant function.